GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit
Mar 4, 2025 • 7:00 EST | Read More
GT Biopharma Announces Exercise of Warrants
Feb 25, 2025 • 2:00 EST | Read More
Change
Volume
52 Week Range
